Zacks Rating on Antares Pharma (ATRS)

Antares Pharma (ATRS) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 3 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Antares Pharma (ATRS) : The highest short term price target forecast on Antares Pharma (ATRS) is $3 and the lowest target price is $2. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $2.67 with a standard deviation of $0.58.


Shares of Antares Pharma Inc. rose by 19.27% in the last five trading days and 30% for the last 4 weeks. Antares Pharma Inc. is up 49.43% in the last 3-month period. Year-to-Date the stock performance stands at 7.44%. Antares Pharma (NASDAQ:ATRS): stock turned positive on Tuesday. Though the stock opened at $1.18, the bulls momentum made the stock top out at $1.44 level for the day. The stock recorded a low of $1.18 and closed the trading day at $1.3, in the green by 12.07%. The total traded volume for the day was 3,935,722. The stock had closed at $1.16 in the previous days trading.

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.